🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

👏🙌NRG GY018!! We did it - improved progression free survival in MMRd AND MMRp #EndometrialCancer. Standard of care == CHANGED! #SGOMtg #gyncsm #ImmunoOnc Congrats to NRG Oncology

JUST IN: U.S. FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell carcinoma (RCC) following PD1 and VEGF inhibitors! A great day for the field and a new option for our Kidney Cancer patients!!!! Via ASCO #FDAAlerts OncoAlert Study presented at ESMO - Eur. Oncology #ESMO3 by

👏 to Toni Choueiri, MD Brian Rini, MD Laurence Albiges for +ve FDA for belzutifan in IO/VEGF pretreated RCC based on +ve PFS not OS (yet). All other TKIs approved without OS btw(except Cabo).The ⬆️ RR/QOL makes it good in 3rd line. It’s best earlier and in combination? bit.ly/3v1NSa3

A big day for bladder ca patients U.S. FDA. Massive team effort. Platinum based chemo superseded at last. EV/pembro will transform the lives of many pts with this difficult disease. Still lots to do but it’s a pretty good day and worth pausing for a moment. bit.ly/3GLntQn

It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2023: Some negative, some positive, but we learned from all! Feel free to add more & retweet & tag This is not an exhaustive list! OncoAlert @danafarber Dana-Farber_GU #OnwardFor2024

In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment. Full trial results: nej.md/49ViJEe

The American Cancer Society Nutrition and Physical Activity guideline for #CancerSurvivors provides evidence-based recommendations about best lifestyle factors for cancer survivors and their families. Read the full recommendations in our free guideline: acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

How can acupuncture, massage, yoga or cryotherapy help with cancer pain? Our Dr. Lorenzo Cohen shares insights. brnw.ch/21wHOHY Lorenzo Cohen Cancer Health #EndCancer

A deep PSA nadir to <0.1ng/ml within 6mths of RT completion is highly prognostic for metastasis-free survival, prostate cancer mortality and overall survival in men receiving RT and ADT for M0 prostate cancer - work from #ICECAP published in Journal of Clinical Oncology: ascopubs.org/doi/10.1200/JC…

.Heidi Ledford tackles an enigma that so many oncologists & researchers are grappling with: Why are so many young people getting cancer? nature.com/articles/d4158… Featuring the voices of Dr. Cathy Eng S. George Barreto Kimmie Ng, MD, MPH Sonia Kupfer Shuji Ogino There’s a new Cancer Grand Challenges

New ESMO gudilelines for Metastatic urothelial carcinoma. Published today in Annals of Oncology ESMO - Eur. Oncology The EV plus pembrolizumab gets included as expected irrespective of platinum eligibility. But the algorithm for places where EV is not available ( most of the LMICs )

Combinação de nivolumabe com QT baseada em cisplatina é aprovada pela ANVISA para câncer de bexiga avançado No fase III CheckMate901, Nivolumabe +QT em 1L demonstrou benefício em SG, SLP e TRO versus QT #GUcsm Fabio Schutz Daniel Vargas Pivato de Almeida Rodrigo Coutinho Mariano mocbrasil.com/blog/geniturin…

Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study ❓Is there any effect of previous local therapy on the response to Apalutamide in pts with mHSPC 🎯 YES! Pts who

PSA After Radiotherapy: Key for Prostate Cancer Survival 6-month PSA level predicts long-term outcomes in patients treated with RT for localized prostate cancer. ⭕️Low PSA (<0.1 ng/mL) linked to better survival rates. ASCO Journal of Clinical Oncology Christopher Sweeney, MBBS Matt Sydes OncoAlert

Darolutamide, enzalutamide, and apalutamide for #nmCRPC patients in the #UnitedStates #DEAR: Comparative real-world evidence. Presentation by Zach Klaassen Georgia Cancer Center. #SESAUA2024 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/3Vw6Osz Southeastern Section #SESAUA24

📢Thrilled to announce that TIDE-A trial is finally out on European Urology! Thanks to all coauthors for supporting 1️⃣st trial of TKI interruption in IO combo for #mRCC. sciencedirect.com/science/articl… Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Tom Powles Brian Rini, MD OncoAlert Università Cattolica Kidney Cancer IKCC Kidney Cancer

Why rush radiotherapy after prostate surgery? ☢️RADICALS-RT trial shows waiting for PSA rise before radiotherapy could be the smarter move – fewer side effects without compromising cancer control. A potential game-changer for post-surgery treatment. #ProstateCancer Matt Sydes

Pending #LBAs, my Top* 10 #ASCO24 (so far) are: *list heavily GU-skewed Dana-Farber ASCO

Nice presentation of FIGO 2023 #endometrialcancer staging. From a review in NatureRevClinOncol. Jeffrey How nature.com/articles/s4157…

ChatGPT Prompts to finish your hours of work in seconds: only Copy and Paste these prompts!